Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Phase 1

Terminated

Conditions: Neoplasms, Malignant

Interventions: Drug: cabazitaxel
Drug: gemcitabine

First Posted Date: 2009-10-26

Last Posted Date: 2013-09-11

Lead Sponsor: Sanofi

Target Recruit Count: 19

Registration Number: NCT01001221

Locations: 🇺🇸
Investigational Site Number 840004, Philadelphia, Pennsylvania, United States
🇺🇸
Investigational Site Number 840005, Cincinnati, Ohio, United States
🇺🇸
Investigational Site Number 840001, Nashville, Tennessee, United States

and more 1 locations

A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)

Completed

Conditions: Smallpox

First Posted Date: 2009-10-20

Last Posted Date: 2012-08-06

Lead Sponsor: Sanofi

Target Recruit Count: 147

Registration Number: NCT00998543

The RECORD Asia-Pacific Atrial Fibrillation Registry

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2009-10-15

Last Posted Date: 2012-02-20

Lead Sponsor: Sanofi

Target Recruit Count: 2674

Registration Number: NCT00995748

Locations: 🇹🇭
Sanofi-Aventis Administrative Office, Bangkok, Thailand

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

Phase 3

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: DOCETAXEL
Drug: CISPLATIN
Drug: 5-FLUOROURACIL

First Posted Date: 2009-10-15

Last Posted Date: 2018-03-02

Lead Sponsor: Sanofi

Target Recruit Count: 240

Registration Number: NCT00995293

Locations: 🇨🇳
Sanofi Administrative Office, Shanghai, China

Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.

Phase 3

Completed

Conditions: Constipation

Interventions: Drug: SENNA+CASSIA
Drug: placebo

First Posted Date: 2009-10-14

Last Posted Date: 2013-03-29

Lead Sponsor: Sanofi

Target Recruit Count: 96

Registration Number: NCT00994851

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin glargine (HOE901)
Drug: Neutral Protamine Hagedorn (NPH) insulin
Drug: Insulin lispro

First Posted Date: 2009-10-12

Last Posted Date: 2012-06-27

Lead Sponsor: Sanofi

Target Recruit Count: 125

Registration Number: NCT00993473

Locations: 🇮🇳
Sanofi-Aventis Investigational Site Number 356001, Bangalore, India
🇮🇳
Sanofi-Aventis Investigational Site Number 356004, Karnal, India
🇲🇽
Sanofi-Aventis Investigational Site Number 484003, Monterrey, Mexico

and more 58 locations

Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

Phase 2

Completed

Conditions: Arrhythmia Prophylaxis
Ventricular Arrhythmia

Interventions: Drug: Celivarone
Drug: Amiodarone
Drug: Matching placebo

First Posted Date: 2009-10-12

Last Posted Date: 2016-05-30

Lead Sponsor: Sanofi

Target Recruit Count: 486

Registration Number: NCT00993382

Locations: 🇺🇸
Investigational Site Number 840045, Chicago, Illinois, United States
🇩🇪
Investigational Site Number 276005, Bad Neustadt, Germany
🇦🇺
Investigational Site Number 036003, Woolloongabba, Australia

and more 148 locations

Colorectal Cancer RECHALLENGE

Phase 2

Withdrawn

Conditions: Colorectal Neoplasms

Interventions: Drug: OXALIPLATIN (SR96669)
Drug: 5-FLUOROURACIL (5-FU)
Drug: LEUCOVORIN (LV)
Drug: BEVACIZUMAB

First Posted Date: 2009-10-02

Last Posted Date: 2009-12-23

Lead Sponsor: Sanofi

Registration Number: NCT00988897

Locations: 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada

Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Terminated

Conditions: Plasmodium Falciparum Infection

Interventions: Drug: Ferroquine (SSR97193)
Drug: Placebo
Drug: artesunate

First Posted Date: 2009-10-02

Last Posted Date: 2011-06-28

Lead Sponsor: Sanofi

Target Recruit Count: 440

Registration Number: NCT00988507

Locations: 🇧🇯
Sanofi-Aventis Investigational Site Number 204001, Cotonou, Benin
🇧🇫
Sanofi-Aventis Investigational Site Number 854001, Ouagadougou, Burkina Faso
🇧🇫
Sanofi-Aventis Investigational Site Number 854003, Nouna, Burkina Faso

and more 7 locations

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Phase 2

Completed

Conditions: Encephalitis
Japanese Encephalitis

Interventions: Biological: Live attenuated Japanese encephalitis virus, then ChimeriVax diluent
Biological: ChimeriVax diluent, then Live attenuated Japanese encephalitis virus

First Posted Date: 2009-09-22

Last Posted Date: 2012-07-16

Lead Sponsor: Sanofi

Target Recruit Count: 202

Registration Number: NCT00981175

Home Terms & Conditions Privacy Policy